Newsletter | August 20, 2019

08.20.19 -- FDA Approves Breakthrough Drug To Treat Extensively Drug-Resistant Tuberculosis

 
Industry Insights
Multiplex Cytokine Immunoassays — Minimizing Effort, Maximizing Results
Article | By Woei Tan and Ivan Huang, Bio-Rad Laboratories, Inc.

The availability of commercial multiplex cytokine assays enables end users to interrogate an entire network of cytokines in a single sample.

Challenges, Risks And Strategies For Biologic Substance Manufacturing
Article | Thermo Fisher Scientific

From discussions with pharmaceutical and biotechnology industry leaders, it is clear that demand forecasting is a significant challenge when planning biologic drug substance production.

Electronic Lab Notebook Supports Scientific Knowledge Management In R&D
Article | Dassault Systemes Americas

One tool holds a unique position among R&D informatics systems -- electronic laboratory notebooks (ELNs). ELNs both produce data and consume information and are particularly powerful.

A Highly Reproducible In Vivo Model For Bleomycin-Induced Lung Fibrosis In Mice To Evaluate Drugs For The Treatment Of IPF
White Paper | GVK Biosciences

Bleomycin-induced pulmonary fibrosis has been a useful pre-clinical model in several species and is most prevalent in rodent models to evaluate potential prophylactic and therapeutic drugs for IPF. The induction and progression of the disease in rodents is of a short duration, making it a practical model for evaluating test compounds in preclinical research. Major drawbacks for this model have been its mortality rate and inconsistency in the induction of the disease. Access to a large portfolio of in vivo fibrosis models allowed for successful drug testing.

Western Blotting Principles And Methods Handbook
E-Book | GE Healthcare Life Sciences

This EBook provides expertise and support, taking you through the complete Western blotting workflow, from sample preparation to detection and analysis.

Life Science Leader Magazine
 

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.